CO5700773A2 - Derivados de bencimidazol - Google Patents
Derivados de bencimidazolInfo
- Publication number
- CO5700773A2 CO5700773A2 CO06068712A CO06068712A CO5700773A2 CO 5700773 A2 CO5700773 A2 CO 5700773A2 CO 06068712 A CO06068712 A CO 06068712A CO 06068712 A CO06068712 A CO 06068712A CO 5700773 A2 CO5700773 A2 CO 5700773A2
- Authority
- CO
- Colombia
- Prior art keywords
- lower alkyl
- heteroaryl
- aryl
- group
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1.- Un compuesto de la fórmula (I) o una sal farmacéuticamente aceptable o éster de profármaco del mismo: en donde:R1 se selecciona a partir del grupo que consiste en (alquilo de 1 a 6 átomos de carbono, alcoxilo inferior, alcoxilo inferior-alquilo inferior, cicloalquiloxi-alquilo inferior, tioalquilo inferior, tioalquilo inferior-alquilo inferior, cicloalquilo, cicloalquil-alquilo inferior, alquenilo inferior, y alquinilo inferior) opcionalmente sustituidos;R2 se selecciona a partir del grupo que consiste en (alquilo inferior, cicloalquilo, cicloalquil-alquilo inferior, arilo, heteroarilo, aril-alquilo inferior, heteroaril-alquilo inferior) opcionalmente sustituidos;R3 se selecciona a partir del grupo que consiste en halógeno, ciano, (alquilo inferior, aIcoxilo inferior, tioaIquiIo inferior, tioaIqueniIo inferior, ariIo, ariI-aIquiIo inferior, heteroarilo, alquenilo inferior, alquinilo inferior, heteroarilo, aril-alquilo inferior, y heteroarilalquilo inferior y amino) opcionalmente sustituidos;R4 se selecciona a partir del grupo que consiste en H, halógeno, ciano, hidroxilo, (alquilo inferior, alcoxilo inferior, tioalquilo inferior, tioalquenilo inferior, arilo, heteroarilo, arilalquilo inferior, heteroaril-alquilo inferior, alquenilo, alquinilo, y amino) opcionalmente sustituidos, y el grupo que tiene la fórmula R8-Z-(CH2)n-;en donde Z representa un enIace directo o se seIecciona a partir del grupo que consiste en O, NH, CH2, CO, SO, SO2, ó S;en donde R8 se selecciona a partir del grupo que consiste en (arilo, heteroarilo, arilo carbocíclico, cicloalquilo, heterocicloalquilo) opcionalmente sustituidos;y en donde n es 0, 1, 2, ó 3;R5 se selecciona a partir del grupo que consiste en H, halógeno, ciano, hidroxilo, (alquilo inferior, alcoxilo inferior, alcoxilo inferior-alquilo inferior, arilo, heteroarilo, aril-alquilo inferior, heteroaril-alquilo inferior, alquenilo, alquinilo, y amino) opcionalmente sustituidos;R6 se selecciona a partir del grupo que consiste en halógeno, ciano, (alquilo inferior, alcoxilo inferior, tioalquilo inferior, alquenilo inferior, alquinilo inferior, alcoxilo inferior-alquilo inferior, arilo, heteroarilo, ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0400781.1A GB0400781D0 (en) | 2004-01-14 | 2004-01-14 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5700773A2 true CO5700773A2 (es) | 2006-11-30 |
Family
ID=31726170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO06068712A CO5700773A2 (es) | 2004-01-14 | 2006-07-14 | Derivados de bencimidazol |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8030497B2 (es) |
| EP (1) | EP1709006A1 (es) |
| JP (1) | JP4531062B2 (es) |
| KR (1) | KR100796398B1 (es) |
| CN (2) | CN102199144A (es) |
| AR (1) | AR049861A1 (es) |
| AU (1) | AU2005205141B2 (es) |
| BR (1) | BRPI0506889A (es) |
| CA (1) | CA2552403A1 (es) |
| CO (1) | CO5700773A2 (es) |
| EC (1) | ECSP066693A (es) |
| GB (1) | GB0400781D0 (es) |
| IL (1) | IL176630A0 (es) |
| MA (1) | MA28291A1 (es) |
| NO (1) | NO20063662L (es) |
| NZ (1) | NZ548319A (es) |
| PE (1) | PE20050762A1 (es) |
| RU (1) | RU2361863C2 (es) |
| SG (1) | SG149831A1 (es) |
| TN (1) | TNSN06220A1 (es) |
| TW (1) | TW200539877A (es) |
| WO (1) | WO2005068433A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0606426D0 (en) * | 2006-03-30 | 2006-05-10 | Novartis Ag | Benzimidazole derivatives |
| WO2009129625A1 (en) * | 2008-04-22 | 2009-10-29 | Merck Frosst Canada Ltd. | Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| CA2762137A1 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| US8785494B2 (en) | 2009-05-27 | 2014-07-22 | Leo-Pharma A/S | Calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| RU2013128981A (ru) | 2010-11-26 | 2015-01-10 | Лео Фарма А/С | Соединения, активные в отношении чувствительных к кальцию рецепторов |
| RU2013128950A (ru) | 2010-11-26 | 2015-01-10 | Лео Фарма А/С | Замещенные циклопентилазины в качестве casr-активных соединений |
| CN103270018A (zh) | 2010-11-26 | 2013-08-28 | 利奥制药有限公司 | 钙敏感受体激活化合物 |
| US20130245084A1 (en) | 2010-11-26 | 2013-09-19 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| AR090789A1 (es) * | 2012-04-23 | 2014-12-10 | Genentech Inc | Intermediarios y procesos para la preparacion de compuestos |
| EA027113B1 (ru) * | 2012-05-04 | 2017-06-30 | Новартис Аг | Регуляторы пути комплемента и их применение |
| US20240293398A1 (en) * | 2017-02-17 | 2024-09-05 | University Of Florida Research Foundation, Incorporated | Defining RNA-Small Molecule Affinity Landscapes Enables Design of a Small Molecule Inhibitor... |
| CN107903177A (zh) * | 2017-12-04 | 2018-04-13 | 武汉药明康德新药开发有限公司 | 4‑甲氧基‑2,3‑二硝基苯甲腈的制备方法 |
| CN109320503B (zh) * | 2018-12-10 | 2022-07-01 | 怀化学院 | 苯并咪唑炔胺类化合物的无金属一锅合成方法 |
| CN110508325B (zh) * | 2019-09-09 | 2022-04-05 | 鲁东大学 | 镍铁氢化酶模型物、离子型镍铁氢化酶模型物及制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR998985A (es) * | 1948-11-09 | 1952-01-24 | ||
| US3080282A (en) * | 1960-04-14 | 1963-03-05 | Merck & Co Inc | Anthelmintic benzimidazole compositions and methods of using same |
| GB962533A (en) * | 1962-04-24 | 1964-07-01 | Imp Chemical Industi Australia | Anthelmintic compositions |
| DE1447733B2 (de) * | 1963-12-23 | 1977-04-21 | Hoechst Ag, 6000 Frankfurt | 2-(3,5-dihydroxyphenyl)-benzimidazolderivate |
| NZ234564A (en) * | 1986-11-21 | 1991-04-26 | Haessle Ab | 1-substituted benzimidazoles and pharmaceutical compositions |
| JPH0751293B2 (ja) * | 1989-09-13 | 1995-06-05 | 三ツ星ベルト株式会社 | 固体充てん材を含む複合材料の成形方法 |
| ES2094694B1 (es) * | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. |
| US6184235B1 (en) * | 1996-08-14 | 2001-02-06 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as MCP-1 antagonists |
| TW453999B (en) * | 1997-06-27 | 2001-09-11 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
| DE19920936A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| US6855714B2 (en) * | 2001-07-06 | 2005-02-15 | Schering Aktiengesellschaft | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
| US20040170689A1 (en) * | 2001-11-09 | 2004-09-02 | Odink Debra Alida | Stabilized formulations comprising hydrolytically unstable compositions |
| US7176322B2 (en) * | 2002-05-23 | 2007-02-13 | Amgen Inc. | Calcium receptor modulating agents |
| US6908935B2 (en) | 2002-05-23 | 2005-06-21 | Amgen Inc. | Calcium receptor modulating agents |
-
2004
- 2004-01-14 GB GBGB0400781.1A patent/GB0400781D0/en not_active Ceased
-
2005
- 2005-01-12 PE PE2005000058A patent/PE20050762A1/es not_active Application Discontinuation
- 2005-01-12 AR ARP050100099A patent/AR049861A1/es not_active Application Discontinuation
- 2005-01-13 EP EP05700898A patent/EP1709006A1/en not_active Withdrawn
- 2005-01-13 TW TW094101020A patent/TW200539877A/zh unknown
- 2005-01-13 NZ NZ548319A patent/NZ548319A/en unknown
- 2005-01-13 US US10/585,480 patent/US8030497B2/en not_active Expired - Fee Related
- 2005-01-13 SG SG200900257-7A patent/SG149831A1/en unknown
- 2005-01-13 BR BRPI0506889-4A patent/BRPI0506889A/pt not_active IP Right Cessation
- 2005-01-13 CN CN2011100629607A patent/CN102199144A/zh active Pending
- 2005-01-13 AU AU2005205141A patent/AU2005205141B2/en not_active Ceased
- 2005-01-13 WO PCT/EP2005/000291 patent/WO2005068433A1/en not_active Ceased
- 2005-01-13 JP JP2006548267A patent/JP4531062B2/ja not_active Expired - Fee Related
- 2005-01-13 KR KR1020067014148A patent/KR100796398B1/ko not_active Expired - Fee Related
- 2005-01-13 CA CA002552403A patent/CA2552403A1/en not_active Abandoned
- 2005-01-13 CN CNA2005800081741A patent/CN1930133A/zh active Pending
- 2005-01-13 RU RU2006129348/04A patent/RU2361863C2/ru not_active IP Right Cessation
-
2006
- 2006-06-29 IL IL176630A patent/IL176630A0/en unknown
- 2006-07-10 MA MA29180A patent/MA28291A1/fr unknown
- 2006-07-11 EC EC2006006693A patent/ECSP066693A/es unknown
- 2006-07-13 TN TNP2006000220A patent/TNSN06220A1/en unknown
- 2006-07-14 CO CO06068712A patent/CO5700773A2/es not_active Application Discontinuation
- 2006-08-14 NO NO20063662A patent/NO20063662L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005068433A9 (en) | 2005-09-15 |
| JP4531062B2 (ja) | 2010-08-25 |
| CA2552403A1 (en) | 2005-07-28 |
| SG149831A1 (en) | 2009-02-27 |
| US20090170921A1 (en) | 2009-07-02 |
| WO2005068433A1 (en) | 2005-07-28 |
| AU2005205141A1 (en) | 2005-07-28 |
| TW200539877A (en) | 2005-12-16 |
| PE20050762A1 (es) | 2005-11-24 |
| RU2361863C2 (ru) | 2009-07-20 |
| CN102199144A (zh) | 2011-09-28 |
| KR100796398B1 (ko) | 2008-01-21 |
| NO20063662L (no) | 2006-10-12 |
| AU2005205141B2 (en) | 2008-12-11 |
| KR20060113993A (ko) | 2006-11-03 |
| JP2007520477A (ja) | 2007-07-26 |
| US8030497B2 (en) | 2011-10-04 |
| CN1930133A (zh) | 2007-03-14 |
| IL176630A0 (en) | 2006-10-31 |
| MA28291A1 (fr) | 2006-11-01 |
| ECSP066693A (es) | 2006-10-31 |
| EP1709006A1 (en) | 2006-10-11 |
| NZ548319A (en) | 2010-05-28 |
| AR049861A1 (es) | 2006-09-13 |
| TNSN06220A1 (en) | 2007-12-03 |
| GB0400781D0 (en) | 2004-02-18 |
| RU2006129348A (ru) | 2008-02-20 |
| BRPI0506889A (pt) | 2007-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5700773A2 (es) | Derivados de bencimidazol | |
| CO5570660A2 (es) | Indazolilpirrolotriazinas c-6 modificadas | |
| CO5580768A2 (es) | Derivados de 4,5-diariltiazol como ligandos cb-1 | |
| ATE288420T1 (de) | Neuartige heterocyclische carboxamid-derivate | |
| CO5640090A2 (es) | Inhibidores del factor inhibidor de la migracion de los macrofagos y etodo para su identificacion | |
| ECSP055974A (es) | Síntesis de cloruros de 4 amino-2-butenoil y su uso en la preparación de 3-ciano quinolinas | |
| CO6150158A2 (es) | Piperidinas sustituidas que aumentan la actividad de p53 y su uso | |
| PE20070135A1 (es) | Compuestos heterociclicos como inhibidores de aspartil proteasas | |
| PE20030857A1 (es) | Compuestos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c | |
| CO5580746A2 (es) | Derivados de fenil-piperazina como inhibidores de la reabsorcion de la serotonina | |
| AR054475A1 (es) | Fenilfosfatos sustituidos como profarmacos mutuos de esteroides y (beta)-agonistas para el tratamiento de la inflamacion pulmonar y la broncoconstriccion | |
| DK1506203T3 (da) | Syntese af epothiloner, mellemprodukter deraf, analoger deraf og anvendelser deraf | |
| JP2004131511A5 (es) | ||
| RU2005105592A (ru) | Макролидные соединения, обладающие противовоспалительной активностью | |
| TW200508359A (en) | Quinoxaline derivatives, and light emitting element using thereof | |
| MA33107B1 (fr) | Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met | |
| AR039111A1 (es) | Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas | |
| EP1775289A4 (en) | NEW IMIDAZOLIDINE DERIVATIVES | |
| CO5570675A2 (es) | Compuestos sustituidos de benzimidazolo y su uso para el tratamiento del cancer | |
| ATE134364T1 (de) | Phenylthioharnstoffderivate und ihre pharmazeutische verwendung | |
| ATE429429T1 (de) | Pharmazeutisches verfahren und damit hergestellte verbindungen | |
| ATE482933T1 (de) | Sulfopyrrolderivate | |
| DK1706414T3 (da) | Fremgangsmåde til fluorcytidinderivater | |
| DE60333546D1 (de) | PyrazoloÄ4,3-DÜpyrimidines, verfahren zur ihre herstellung und deren verwendung | |
| CY1109126T1 (el) | Βιοτιλιωμενοι εξαδεκασακχαριτες, φαρμακευτικες συνθεσεις και η εφαρμογη τους |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted | ||
| FD | Application lapsed |